Please read before exploring Peptide Insights
Important: The information on this website is intended for educational and research purposes only.
Peptide Insights provides information about peptides based on published scientific research and clinical literature. This content is designed to help you understand the science, not to guide personal medical decisions.
By continuing, you confirm that you are accessing this information for educational purposes and understand that it does not constitute medical advice.
From weight loss to cardiovascular protection — the expanding science of GLP-1 agonists
When semaglutide was first approved by the FDA in 2017 for type 2 diabetes management, few anticipated that it would become one of the most consequential drugs in modern medicine. By 2021, the approval of Wegovy (high-dose semaglutide) for chronic weight management had transformed the conversation around obesity treatment. And in 2026, the research continues to expand in directions that are reshaping our understanding of what GLP-1 agonists can do.
Here is a summary of the most significant developments from the past year of semaglutide research.
The SELECT trial, published in the New England Journal of Medicine, was a landmark study that followed over 17,000 overweight or obese adults without diabetes for an average of 3.3 years. The results were striking: semaglutide reduced the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% compared to placebo — independent of the amount of weight lost.
This finding is significant because it suggests that semaglutide's cardiovascular benefits are not simply a consequence of weight reduction. The peptide appears to have direct cardioprotective effects, possibly through its anti-inflammatory properties and direct effects on cardiac tissue. This has led to FDA approval of semaglutide for cardiovascular risk reduction in adults with established cardiovascular disease and obesity.
The FLOW trial demonstrated that semaglutide significantly reduces the progression of chronic kidney disease in people with type 2 diabetes and kidney disease. The trial was stopped early because the benefits were so clear that it was deemed unethical to continue withholding treatment from the placebo group — a rare and significant event in clinical trial history.
The kidney-protective effects appear to involve reduced inflammation, improved blood pressure control, and direct effects on kidney cell function. Researchers are now investigating whether these benefits extend to people with kidney disease who do not have diabetes.
Perhaps the most surprising emerging area of semaglutide research is its potential role in neurodegenerative disease. Multiple observational studies have found that people taking GLP-1 agonists have significantly lower rates of Alzheimer's disease and Parkinson's disease compared to matched controls. A large Danish registry study found a 50–70% reduction in Alzheimer's diagnosis among long-term GLP-1 agonist users.
The proposed mechanisms are multiple: GLP-1 receptors are expressed in the brain, and semaglutide may reduce neuroinflammation, improve insulin signaling in the brain (which is impaired in Alzheimer's), and promote the clearance of amyloid plaques. Clinical trials specifically investigating semaglutide for Alzheimer's prevention are now underway.
The neurological data on GLP-1 agonists is preliminary but remarkable. If even a fraction of the observational signal translates to clinical trials, we may be looking at one of the most significant developments in dementia prevention in decades.
A consistent and unexpected finding across multiple studies is that GLP-1 agonists appear to reduce addictive and compulsive behaviors beyond food. Users report reduced cravings for alcohol, nicotine, and other substances. Observational data supports this: people on semaglutide have lower rates of alcohol use disorder diagnosis and treatment, and lower rates of smoking cessation failure.
The mechanism likely involves GLP-1 receptors in the reward circuitry of the brain, particularly in the nucleus accumbens and ventral tegmental area. Clinical trials investigating semaglutide for alcohol use disorder and smoking cessation are now in progress.
With millions of people now having used semaglutide for extended periods, the real-world safety data is becoming clearer. The most common side effects — nausea, vomiting, diarrhea, and constipation — are well-established and typically most severe in the first few weeks of treatment. They can be minimized with slow dose escalation.
The concern about muscle mass loss with rapid weight loss has been partially addressed by studies showing that combining semaglutide with resistance training largely preserves lean mass. This is now considered a standard recommendation for people on GLP-1 agonist therapy.
The rare but serious risks (pancreatitis, thyroid C-cell tumors in rodent models, gastroparesis) remain areas of ongoing monitoring. The thyroid cancer signal has not materialized in human data to date, but long-term surveillance continues.
Semaglutide has moved well beyond its origins as a diabetes and weight loss medication. The emerging evidence suggests it may be one of the most broadly beneficial compounds in modern medicine — with potential applications in cardiovascular disease, kidney disease, neurodegeneration, and addiction. The research is moving fast, and the full picture of what GLP-1 agonists can do is still being written.
If you are considering semaglutide for any indication, the conversation with your healthcare provider has become significantly more nuanced — and more interesting — than it was even two years ago.